Literature DB >> 2400999

Gene amplification in gastric and esophageal adenocarcinomas.

J Houldsworth1, C Cordon-Cardo, M Ladanyi, D P Kelsen, R S Chaganti.   

Abstract

In a United States series of 28 gastric/esophageal adenocarcinomas of poorly to moderately differentiated histopathology, we detected gene amplification in 21% of the tumors. Using the modified DNA in-gel renaturation assay to detect down to 7-8 copies of amplified DNA sequences, we identified 3 gastric tumors with amplified DNA sequences and confirmed by Southern hybridization analysis that HER-2/neu was amplified greater than 5-fold in these specimens. Immunohistochemical staining of tumor tissue sections with p185 HER-2/neu antibodies demonstrated that only the 3 gastric adenocarcinomas with corresponding HER-2/neu gene amplification displayed membrane immunoreactivity. Amplification of c-met was identified in 2 tumors, and this was the first study to assay for multiple copies of this protooncogene in fresh gastric tumor tissues. Amplification of c-erbB was observed in one tumor, and no evidence for amplification of int-2 was obtained in this series of adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400999

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

3.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Authors:  Anurag Singh; Patricia Greninger; Daniel Rhodes; Louise Koopman; Sheila Violette; Nabeel Bardeesy; Jeff Settleman
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

5.  Amplification and overexpression of the c-erbB-2 protooncogene in human gastric cancer.

Authors:  K Sasaki; Y Tomita; M Azuma; S Shida; B Simizu
Journal:  Gastroenterol Jpn       Date:  1992-04

6.  Promise and challenges on the horizon of MET-targeted cancer therapeutics.

Authors:  Yu-Wen Zhang
Journal:  World J Biol Chem       Date:  2015-05-26

7.  Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.

Authors:  Debora de Melo Gagliato; Denis L Fontes Jardim; Gerald Falchook; Chad Tang; Ralph Zinner; Jennifer J Wheler; Filip Janku; Vivek Subbiah; Sarina A Piha-Paul; Siqing Fu; Kenneth Hess; Sinchita Roy-Chowdhuri; Stacy Moulder; Ana M Gonzalez-Angulo; Funda Meric-Bernstam; David S Hong
Journal:  Clin Breast Cancer       Date:  2014-06-23       Impact factor: 3.225

8.  Expression of MMP9, SERPINE1 and miR-134 as prognostic factors in esophageal cancer.

Authors:  Anna Agnieszka Klimczak-Bitner; Radzisław Kordek; Jan Bitner; Jacek Musiał; Janusz Szemraj
Journal:  Oncol Lett       Date:  2016-09-29       Impact factor: 2.967

9.  Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).

Authors:  Michael S Roberts; David C Turner; Alberto Broniscer; Clinton F Stewart
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-04-28       Impact factor: 3.205

10.  Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma.

Authors:  J Jaehne; C Urmacher; H T Thaler; H Friedlander-Klar; C Cordon-Cardo; H J Meyer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.